Ensocell is a Cambridge, United Kingdom biotech company founded in 2023 to translate the resolution of single-cell genomics into new medicines. The company's premise is that disease biology becomes far more tractable when it is understood at the level of individual cells and their spatial organization in tissue, rather than averaged across bulk samples. By combining these high-resolution measurement technologies with artificial intelligence, Ensocell aims to pinpoint the precise cellular and molecular intervention points where new therapies can have the greatest effect.
At the center of the company is its proprietary ENSO AI platform, which integrates single-cell and spatial genomics technologies with AI-based computational tools and advanced human cell models. This integrated stack lets Ensocell map how diseased tissues differ from healthy ones at cellular resolution, identify the cell types and pathways driving pathology, and prioritize novel targets that conventional approaches might overlook. The company focuses on autoimmune, inflammatory, and fibrotic diseases, areas where complex cellular interactions have made target discovery especially difficult.
Ensocell draws on the scientific heritage of the Wellcome Sanger Institute, one of the world's leading genomics research centers, and its founding team includes leading figures in single-cell genomics and computational biology. This combination of deep domain expertise and modern AI tooling positions the company to convert cutting-edge genomics data into actionable drug-discovery hypotheses.
The company raised funding backed by OMX Ventures and Sofinnova, capital that supports the build-out of its ENSO platform and the advancement of its discovery programs. By using AI to interpret single-cell and spatial data at scale, Ensocell seeks to find disease intervention points that lead to genuinely novel therapeutics for hard-to-treat immune and fibrotic conditions.